President Trump's announcement that he will nominate Todd Blanche as permanent attorney general is not, for the cannabis industry, a question about whether medical marijuana gets rescheduled. That question was answered on April 22, 2026, when the Department of Justice - with Blanche serving as acting attorney general - issued its final order moving DEA-approved medications and state-licensed medical marijuana from Schedule I to Schedule III. What Blanche's potential confirmation actually determines is something more operational and, frankly, more immediate: whether that order holds, how the legal challenges around it get defended, and whether the same administrative machinery ever turns toward psychedelics.

For dispensary operators and multi-state operators already rebuilding their financial and compliance structures around the end of 280E, the durability question is the one that keeps CFOs up at night. Blanche signed the April 22 order. A confirmed attorney general does not typically spend political capital unwinding his own prior work - and that reality matters considerably to licensed cannabis businesses that have already made bets on the new tax posture. Operators in regulated markets, from vertically integrated MSOs to single-store independents using dispensary pos software new york to manage compliance-sensitive inventory and sales data, need the legal ground under them to stay level. A new AG arriving with no ownership of the April 22 order would represent precisely the kind of uncertainty that delays investment, complicates banking conversations, and makes wholesale pricing agreements harder to finalize.

That said, confirmation is not a certainty. And even a confirmed Blanche inherits real, live problems. The rescheduling order is already facing legal challenges - including litigation from state attorneys general - and the adult-use question remains open through a separate administrative process entirely. Whoever permanently holds the job will determine how DOJ defends the rescheduling in court, what posture the agency takes on adult-use proceedings, and where federal enforcement priorities land on state-licensed operators that sit outside the rescheduled category. The AG's identity doesn't change whether medical rescheduling happened; it shapes how well it holds and what the practical implementation looks like on the ground.

What the Rescheduling Order Actually Changed - and What It Left Open

The April 22 final order carries immediate operational weight for medical cannabis businesses. The end of 280E tax treatment for Schedule III-compliant operators changes the economics of licensed retail in ways that wholesale pricing, payroll, and lease structuring all have to absorb. The new DEA registration pathway creates compliance obligations that operators are still mapping. And state-licensed programs have to reconcile their existing seed-to-sale tracking requirements and COA standards against a federal framework that now, for the first time, formally acknowledges their existence as something other than Schedule I criminal activity.

Here's the catch, though: the order did not resolve everything. Adult-use remains legally distinct from medical cannabis under the current framework, and the administrative process addressing that question is still running. Operators whose licenses cover both medical and adult-use sales - which describes most dispensaries in mature markets - are in an asymmetric position. The 280E relief and registration pathway apply to the medical side of their business in ways that may not, depending on how the adult-use process resolves, extend cleanly to the rest. Compliance teams are already tracking this split carefully, and for good reason.

Psychedelics: The Machinery Turned Once. That's Not Nothing.

Psilocybin, MDMA, ibogaine - none of them were touched by the April 22 order. Their Schedule I classification stands. But the order proved something concrete that the psychedelics industry has been watching closely: this DOJ is willing to use existing statutory authority to move a substance out of Schedule I when the evidence and the political conditions align. For an industry accustomed to a federal posture that treated rescheduling petitions as bureaucratic dead letters, a working example of the process actually completing is meaningful context.

The clearest live mechanism is Dr. Sunil Aggarwal's petition to reschedule psilocybin, which DEA transmitted to HHS for medical and scientific evaluation in 2025. Under the statutory framework, HHS's scientific recommendation binds DEA on scientific questions - but the decision to issue a proposed rescheduling rule rests with DEA, an agency that answers to the attorney general. Separately, the president's April 18 executive order directed federal agencies to reduce barriers to psychedelic research, and FDA followed by granting priority vouchers to several psychedelic drug programs. None of that obligates a Blanche DOJ to reschedule psilocybin. The Congressional Research Service has noted that DOJ retains discretion to decline action or restart a review. The marijuana order makes psychedelic rescheduling easier to imagine; a permanent AG's priorities will help determine whether it ever moves from imaginable to done.

The Practical Read for Cannabis Businesses

A Blanche confirmation, if it happens, represents continuity over disruption for medical cannabis operators - and continuity, right now, has real monetary value. The 280E restructuring alone is rewriting the P&L math for licensed dispensaries that have operated for years under a tax burden their non-cannabis retail competitors never faced. Locking in an attorney general who authored the order that removed that burden forecloses the scenario most damaging to near-term investment and operational planning: a new chief law enforcement officer with no stake in the prior decision and every reason to treat it as unsettled.

What it doesn't do is answer the adult-use question, insulate the order from ongoing litigation, or guarantee that the same administrative process ever runs for psychedelics. The distance between what a regulatory order says and what it actually does in practice - in courtrooms, in bank underwriting decisions, in state-federal compliance interactions - is where the industry's work now lives. A Blanche tenure doesn't close that distance on its own. But it removes one significant variable from the equation, and for licensed operators trying to plan past the next quarterly tax filing, that is not a trivial thing.